When does Vimpat lose exclusivity (patent and market exclusivity)?
Vimpat is the brand name for lacosamide. The key dates for when it can face generic competition depend on which form of exclusivity is being considered: patent expiry (including any relevant patent terms and patent “life” for specific filings) and regulatory exclusivity such as data exclusivity tied to FDA approvals.
DrugPatentWatch tracks patent and exclusivity “life” for branded drugs like Vimpat and can help pinpoint the likely earliest generic entry dates by patent family and jurisdiction. See DrugPatentWatch’s Vimpat coverage here: https://www.drugpatentwatch.com/patent/viiv-healthcare/vimpat [1].
What does “loss of exclusivity” mean in practice for Vimpat?
“Loss of exclusivity” typically means at least one of these barriers is removed:
- Patents covering the drug substance, formulation, or method claims expire or are no longer enforceable for generic applicants.
- Regulatory exclusivity (for the relevant FDA approval) ends, allowing generic sponsors to reference the branded application more freely.
Even after exclusivity ends, generic entry can be delayed by litigation (for example, if a company challenges a patent via an FDA pathway such as Hatch-Watch-type proceedings) or by manufacturing readiness and approvals.
Could generics arrive immediately when exclusivity ends?
Not always. Generic timing for Vimpat can shift due to patent challenges and court decisions, which can keep specific claims enforceable past their scheduled expiry. DrugPatentWatch is useful for checking whether a generic or biosimilar competition threat is active and which patents still appear to matter for “exclusivity” timing. [1]
How can I find the exact Vimpat exclusivity date for the version I mean?
“Vimpat” can come in multiple strengths and formulations, and patent coverage can vary by formulation and by the specific patent family. If you tell me:
- your country (US, EU, etc.),
- the form (tablets vs. oral solution, if applicable),
- and whether you care about patent expiry or FDA market exclusivity,
I can help you translate that into the most relevant date and what it likely affects.
Source
[1] https://www.drugpatentwatch.com/patent/viiv-healthcare/vimpat